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The OTT-MAL fusion oncogene activates RBPJ-mediated
transcription and induces acute megakaryoblastic leukemia in a
knockin mouse model
Abstract
Acute megakaryoblastic leukemia (AMKL) is a form of acute myeloid leukemia (AML) associated with
a poor prognosis. The genetics and pathophysiology of AMKL are not well understood. We generated a
knockin mouse model of the one twenty-two-megakaryocytic acute leukemia (OTT-MAL) fusion
oncogene that results from the t(1;22)(p13;q13) translocation specifically associated with a subtype of
pediatric AMKL. We report here that OTT-MAL expression deregulated transcriptional activity of the
canonical Notch signaling pathway transcription factor recombination signal binding protein for
immunoglobulin kappa J region (RBPJ) and caused abnormal fetal megakaryopoiesis. Furthermore,
cooperation between OTT-MAL and an activating mutation of the thrombopoietin receptor
myeloproliferative leukemia virus oncogene (MPL) efficiently induced a short-latency AMKL that
recapitulated all the features of human AMKL, including megakaryoblast hyperproliferation and
maturation block, thrombocytopenia, organomegaly, and extensive fibrosis. Our results establish that
concomitant activation of RBPJ (Notch signaling) and MPL (cytokine signaling) transforms cells of the
megakaryocytic lineage and suggest that specific targeting of these pathways could be of therapeutic
value for human AMKL.
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Acute	megakaryoblastic	leukemia	(AMKL)	is	a	form	of	acute	myeloid	leukemia	(AML)	associated	with	a	poor	
prognosis.	The	genetics	and	pathophysiology	of	AMKL	are	not	well	understood.	We	generated	a	knockin	mouse	
model	of	the	one	twenty-two–megakaryocytic	acute	leukemia	(OTT-MAL)	fusion	oncogene	that	results	from	
the	t(1;22)(p13;q13)	translocation	specifically	associated	with	a	subtype	of	pediatric	AMKL.	We	report	here	that	
OTT-MAL	expression	deregulated	transcriptional	activity	of	the	canonical	Notch	signaling	pathway	transcrip-
tion	factor	recombination	signal	binding	protein	for	immunoglobulin	κ	J	region	(RBPJ)	and	caused	abnor-
mal	fetal	megakaryopoiesis.	Furthermore,	cooperation	between	OTT-MAL	and	an	activating	mutation	of	the	
thrombopoietin	receptor	myeloproliferative	leukemia	virus	oncogene	(MPL)	efficiently	induced	a	short-latency	
AMKL	that	recapitulated	all	the	features	of	human	AMKL,	including	megakaryoblast	hyperproliferation	and	
maturation	block,	thrombocytopenia,	organomegaly,	and	extensive	fibrosis.	Our	results	establish	that	concom-
itant	activation	of	RBPJ	(Notch	signaling)	and	MPL	(cytokine	signaling)	transforms	cells	of	the	megakaryocytic	
lineage	and	suggest	that	specific	targeting	of	these	pathways	could	be	of	therapeutic	value	for	human	AMKL.
Introduction
Acute megakaryoblastic leukemia (AMKL) is a heterogeneous 
subtype of acute myeloid leukemia (AML) and is more frequent 
in children than in adults (1–3). The molecular basis of AMKL is 
poorly understood in adults, whereas 2 major molecular subtypes 
are recognized in pediatric AMKL. The first group is represented 
by Down syndrome (DS) patients with both transient myelopro-
liferative disease (transient MPD) and AMKL who present with 
acquired GATA-binding protein 1 (GATA1) mutations, result-
ing in an N-terminal truncated GATA1 short (GATA1s) protein 
(4). The second group occurs in infants and is associated with 
the t(1;22)(p13;q13) chromosomal translocation, resulting in 
expression of the one twenty-two megakaryocytic acute leukemia 
(OTT-MAL) (also known as RBM15-MKL1) fusion protein (5–7). 
MAL is a cofactor of the serum response factor (SRF) endowed 
with strong transcriptional activation properties (8), and its local-
ization and function are deregulated by fusion with OTT (9). OTT 
is related to the SHARP transcription factor that has been shown 
to interact with recombination signal binding protein for immu-
noglobulin κ J region (RBPJ), the transcription factor involved in 
response to the canonical Notch pathway, and repress transcrip-
tion of its target genes in absence of Notch signaling (10–13).
The thrombopoietin (TPO) receptor myeloproliferative leu-
kemia virus oncogene (MPL) and its ligand, TPO, are essen-
tial for the proliferation of megakaryocyte (Mk) progenitors 
(MkPs) and their differentiation into mature platelet-produc-
ing Mks (14). Ligand stimulation of MPL results in activation 
of the Janus kinases JAK2 and TYK2, followed by docking and 
phosphorylation of a spectrum of signaling proteins (15–17). 
The relevance of this pathway to pathogenesis of AMKL is high-
lighted by demonstration of activating point mutations in JAK2 
or JAK3 (18–20) and in MPL (21). In addition, secondary AMKL 
may also occur with leukemic transformation of chronic myelo-
proliferative syndromes, including polycythemia vera, essential 
thrombocytosis, and myeloid metaplasia, that are frequently 
associated with activating mutations in JAK2 or MPL (22, 23). 
These observations indicate that activating mutations in the 
TPO/MPL/JAK signaling pathway play an important role in Mk 
malignancies in humans.
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To gain insight into the requirements for AMKL leukemo-
genesis, we generated a conditional knockin allele of Ott-MAL 
in mice. We observe that OTT-MAL expression from its endog-
enous promoter results in aberrant megakaryopoiesis associated 
with enhanced self renewal and activation of RBPJ-mediated 
transcription. In addition, analysis of gene expression data from 
infants with AMKL supports a role for deregulation of Notch 
signaling in transformation of the megakaryocytic lineage. We 
further observe that expression of OTT-MAL with concomitant 
Notch signaling deregulation cooperates with an activating 
allele of MPL to induce a highly penetrant AMKL that recapitu-
lates the human phenotype.
Results
Conditional expression of Ott-MAL in a knockin mouse model. We engi-
neered a conditional Ott-MAL knockin mouse model that allowed 
for expression of the fusion protein from the endogenous murine 
Ott promoter after Cre recombinase–mediated excision of a STOP 
cassette flanked by loxP recombination sites (floxed-STOP; Figure 
1A). Southern blot analysis of XmnI-digested ES cell DNA iden-
tified clones with homologous recombination (Figure 1, B and 
C). Functional integrity of the targeted construct was confirmed 
by transducing Ott3lox/WT ES clones with adenovirus encoding the 
Cre recombinase, followed by selection of OttOtt–MAL excised clones 
based on Southern blot analysis (Figure 1D). Conditional expres-
sion of the fusion mRNA and protein was confirmed by RT-PCR 
and Western blot analysis, respectively (Figure 1, E and F). Animals 
with germline transmission of the Ott3lox allele were crossed to an 
EIIA-Cre transgenic mouse line, resulting in in vivo excision of the 
floxed-STOP cassette, with germline transmission of the OttOtt–MAL 
allele. OttOtt–MAL/WT animals (termed OM) were observed at pre-
dicted Mendelian ratios and were backcrossed into the C57BL/6 
background for further analysis.
OTT-MAL expression results in abnormal fetal and adult hematopoiesis 
but induces AMKL with low penetrance. As the OTT-MAL fusion is 
restricted to infant leukemias and is likely to occur in utero, we 
first analyzed fetal liver hematopoiesis using flow cytometry. 
Plating of purified Lineage–Sca1+c-Kit+ (LSK) cells from E12.5 
fetal livers revealed a significant increase in colony-forming 
efficiency due to expansion of multipotent myeloid progenitors 
(CFU–granulocyte-macrophage-erythroid-Mk [CFU-GEMM]) in 
OM versus WT cells (Figure 2A), although no differences were 
observed in the absolute number of hematopoietic progenitors 
or CD41+ cells between OM and WT fetal liver at day E12.5 (Sup-
plemental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI35901DS1; and data not shown). 
Furthermore, replating of LSK cell–derived primary colonies 
from OM embryos showed an increase in both Mk-containing 
(CFU-GEMM) and pure Mk (CFU-Mk) secondary colonies (Fig-
ure 2B), whereas no CFU-Mk were obtained with plating of WT 
cells. Identification of Mk-containing colonies was confirmed 
by staining cytospins of single colonies for acetylcholinester-
ase (AchE) activity (data not shown). These data indicate that 
OTT-MAL expression results in aberrant differentiation of HSC 
toward the megakaryocytic lineage in vitro.
We next investigated the effect of OTT-MAL expression on 
adult hematopoiesis. As OM animals did not show hematologi-
cal abnormalities during the first 6 months of life (data not 
shown), we studied an older cohort of 15 OM, 10 Ott3lox/WT, and 
10 WT littermate animals aged 18–24 months. Since extramed-
ullary hematopoiesis leading to splenomegaly is a hallmark of 
AMKL in humans, we first evaluated the number of progenitors 
in splenocytes and observed an increase in OM animals (Fig-
ure 2C). In addition, these cells also showed enhanced replating 
activity in the majority of OM animals (8/15), whereas no replat-
ing activity was observed in cells derived from WT littermate 
(0/10) or Ott3lox animals (0/10) (Figure 2C). Colonies derived 
from OM animals at the fifth round of replating showed AchE+ 
cells, indicating their megakaryocytic nature (data not shown). 
In addition, histopathologic analysis revealed that animals 
with increased replating activity of splenocytes had abnor-
malities in the hematopoietic system including extramedullary 
Figure 1
Ott-MAL knockin approach. (A) Mouse Ott locus (show-
ing splicing between exon 1 and 2), OTT-MAL targeting 
construct/Ott3lox allele, and OM allele are represented. 
OMF and OMR show locations of primers used for detec-
tion of the fusion transcript by RT-PCR. X, XmnI site. (B 
and C) Southern blot analysis of ES clone DNA using 
XmnI digestion show correct homologous recombination 
on the 5′ and 3′ sides of the targeting construct, respec-
tively. Rec, recombined. (D–F) Southern blot, RT-PCR, 
and Western blot analysis, respectively, on ES clones 
obtained after adeno-Cre–mediated excision of the 
Hygro-STOP cassette. Arrow indicates the OTT-MAL 
(OM) fusion protein. Asterisk indicates nonspecific band; 
IVT, in vitro transcription control.
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Figure 2
OTT-MAL induces abnormal fetal and adult hematopoiesis and AMKL with low penetrance. (A) Plating efficiency of LSK cells. Mean ± SD of the 
number and type of colony counted after 7 days in triplicate is shown. (B) Colonies from A were replated into fresh methylcellulose plates and 
were scored 7 days later. Mean ± SD of 3 independent experiments is shown. Mk, CFU-Mk; E, blast-forming unit–erythroid; GM, CFU–granu-
locyte-macrophage. (C) Serial replating assays of splenocytes from 18- to 24-month-old OM, Ott3lox/WT, and WT littermate animals. Mean value 
of the number of colonies is indicated. (D) Kaplan-Meier survival curves of secondary (IIary) and tertiary (IIIary) recipients injected with 1 × 106 
splenocytes from 6127 (WT) and 6133 (OM). (E) Immunohistochemistry on BM sections from secondary recipients using vWF antibody. Cells 
expressing vWF show a dark brown coloration. Original magnification, ×100; ×1000 (insets). (F) Proliferation of 6133 cells in absence or pres-
ence of SCF (10 ng/ml). Of note, proliferation of 6133 cells was not dependent on TPO. (G) Wright-Giemsa staining of the 6133 cell line. Original 
magnification, ×1000. (H) Flow cytometrical immunophenotype of 6133 cells. Percentages of live cells are indicated.
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hematopoiesis in the spleen and liver (6/15) and frank leukemia 
(2/15: nos. 6133 and 8904). These leukemias had phenotypic 
attributes of human AMKL, including infiltration of the BM, 
spleen, liver, and kidney with an admixture of immature mega-
karyocytic and erythroid elements as well as megakaryoblasts 
circulating in the peripheral blood (Supplemental Figure 2). The 
disease was transplantable into secondary and tertiary recipi-
ents, with a median survival of 45 days and 24 days, respectively 
(Figure 2D). Secondary recipients showed a phenotype similar 
to that of primary animals, with infiltrating leukemic blasts that 
were vWF+, confirming the megakaryoblastic nature of the dis-
ease (Figure 2E and Supplemental Figure 3).
A cytokine-dependent cell line was derived from leukemic cells 
of animal no. 6133 (Figure 2F). Similar to primary leukemic cells 
from this animal, the 6133 cell line displayed an immature phe-
notype (Figure 2G). These cells were positive for c-Kit as well as 
several megakaryocytic markers, including CD41 and CD42b, and 
were negative for myeloid markers, including Mac1 and FcεRIa 
Figure 3
OTT-MAL activates RBPJ-mediated transcriptional activity. (A) Immunoprecipitation analyses in 293T cells transfected with OTT-MAL and 
OTT-MALΔRRM mutant show interaction between OTT-MAL and RBPJ through the N-terminal region of OTT (see B). STAT5 antibody was 
used as a nonspecific control. (B) Schematic representation of OTT, MAL, OTT-MAL (OM), and OM mutants. (C) 293T cells were transfected 
with the indicated constructs. Luciferase assays were performed 48 hours after transfection. Mean ± SD light intensity of 3 independent experi-
ments is shown. Inset, expression analysis of the different constructs in 293T cells by Western blot (anti-HA antibody). (D) TNR mice (GFP 
under the control of RBPJ-responsive elements) were crossed to OM animals, and GFP fluorescence intensity was analyzed in lineage-negative 
hematopoietic progenitors from WT, TNR, and OM+TNR mice. (E) RNA was extracted from lineage-negative cells of OM and WT littermate 
control animals and analyzed by quantitative RT-PCR for Notch target genes compared with Gapdh. Mean ± SD of 3 independent experiments 
is shown. (F) Immunoprecipitation analyses of 6133 cell lysate indicate interaction between RBPJ and OTT-MAL in AMKL cells. (G) Chromatin 
immunoprecipitation assays were performed with 6133 cells and Ba/F3 cells and analyzed by quantitative PCR using primers surrounding a 
RBPJ binding site in the endogenous promoter of the Hes1 gene. Mean ± SD of triplicate quantitative PCR from a representative experiment 
are shown. (H) 6133 cells were transduced with a retrovirus expressing a dnRBPJ mutant. GFP-positive cells were flow sorted, and proliferation 
was monitored using trypan blue exclusion assay. Mean ± SD relative to noninfected cells is represented (n = 3).
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(Figure 2H). Together, these results indicate that expression of 
OTT-MAL results in abnormal differentiation of fetal hematopoi-
etic progenitors, enhanced self-renewal properties of MkPs, and 
extramedullary hematopoiesis, leading to development of AMKL 
with low penetrance and long latency.
OTT-MAL activates RBPJ-mediated transcriptional activity. OTT 
belongs to a family of proteins that interact with the transcrip-
tion factor RBPJ (11–13, 24), and constitutive activation of RBPJ-
mediated transcription due to Notch signaling has been reported 
to result in increased self renewal and cancer (25, 26). To better 
understand the mechanism of megakaryocytic transformation 
by OTT-MAL, we determined whether OTT-MAL could interfere 
with RBPJ-mediated transcriptional regulation. Coimmuno-
precipitation experiments in 293T cells showed that OTT-MAL 
formed a complex with RBPJ that required the RNA recognition 
motif (RRM) domains of OTT-MAL (Figure 3, A and B). Further-
more, transactivation assays in 293T cells using an RBPJ lucif-
erase reporter showed that OTT-MAL activated RBPJ-mediated 
transcription in a dose-dependent manner, whereas expression of 
OTT resulted in a subtle inhibition of RBPJ transcription (Figure 
3C) (13). Transactivation of the RBPJ reporter by OTT-MAL was 
dependent on the transactivation domain (TAD) of MAL and the 
RRM domains of OTT (Figure 3, B and C).
To investigate whether the RBPJ target genes could be tran-
scriptionally activated by OTT-MAL in vivo, we first crossed OM 
animals with an established transgenic Notch reporter (TNR) 
mouse model, in which the expression of a GFP reporter is 
under the control of RBPJ response elements (27, 28). GFP fluo-
rescence was higher in lineage-negative hematopoietic cells from 
double OM+TNR animals than in cells from control TNR ani-
mals (Figure 3D). In addition, primary lineage negative hemato-
poietic cells from OM animals showed increased expression of 
Hes1, Hes5, and Dtx1 transcripts compared with WT animals 
(Figure 3E), confirming activation of RBPJ transcription by 
OTT-MAL in vivo. Of note, Gata1 and Gata2 transcripts were 
also upregulated in OM versus WT cells (Supplemental Figure 
4A). These results demonstrate increased RBPJ transcriptional 
activity in the hematopoietic progenitors of OM animals with 
respect to WT controls.
We next assessed whether OTT-MAL activation of RBPJ tran-
scription is involved in the proliferation of 6133 AMKL cells. We 
performed coimmunoprecipitation to confirm that endogenous 
OTT-MAL but not MAL interacted with RBPJ in the 6133 AMKL 
cell line (Figure 3F). In addition, chromatin immunoprecipitation 
analyses indicated that MAL and RBPJ were present at the HES1 
promoter in 6133 cells but were not present at the HES1 promoter 
in control Ba/F3 cells that do not express OTT-MAL (Figure 3G). 
As confirmation, we also transduced 6133 cells with a dominant 
negative (dn) form of RBPJ (dnRBPJ) that is unable to bind DNA 
(29) or with a dn Mastermind-like 1 (dnMAML1) mutant that 
entraps intracellular Notch (ICN) and RBPJ in transcriptionally 
inactive complexes when Notch signaling is activated (30, 31). 
Compared with empty vector control, dnRBPJ expression specifi-
cally inhibited the growth of 6133 AMKL cells but not control 
Figure 4
Gene expression analysis of human AMKL with t(1;22)(p13;q13) demonstrates a Notch pathway signature. (A) GSEA using a list of genes impli-
cated in Notch signaling and comparing AMKL with t(1;22)(p13;q13) (OM-AMKL) with DS-AMKL. (B) Heat map representation of the 30 most 
enriched Notch genes in OM compared with DS-AMKL. Blue represents low expression; red represents high expression.
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Ba/F3 cells (Figure 3H and Supplemental Figure 4). In contrast, 
dnMAML1 or γ-secretase inhibitors had no significant effect on 
growth of 6133 or Ba/F3 cells (Supplemental Figure 4 and data 
not shown), suggesting that the expression of RBPJ target genes is 
not dependent on the activation of Notch receptors but is due to 
direct interaction between OTT-MAL and RBPJ.Taken together, 
these results indicate that RBPJ-mediated transcription is aber-
rantly induced by OTT-MAL in vitro and in vivo and is required 
for the growth of OTT-MAL–transformed AMKL cells.
An RBPJ pathway signature is upregulated in t(1;22)(p13;q13) 
AMKL. This mouse model expressing OTT-MAL indicates that 
aberrant activation of the RBPJ transcription factor, a media-
tor of the canonical Notch signaling pathway, is important for 
leukemic transformation of the Mk lineage. To confirm the 
role of the pathway in human AMKL, we analyzed the expres-
sion of RBPJ pathway genes in human AMKL associated with 
t(1;22)(p13;q13) (OM-AMKL) compared with DS-AMKL, the 
other molecularly defined subgroup of childhood AMKL. Using 
published global expression data from AMKL samples (32), we 
performed Gene Set Enrichment Analysis (GSEA) using a list of 
genes implicated in the RBPJ pathway (Supplemental Table 1). 
GSEA results showed that a RBPJ pathway signature was signifi-
cantly enriched in OM-AMKL compared with DS-AMKL (Figure 
4A). The most upregulated genes in OM-AMKL included Notch1, 
Figure 5
MPL mutant transforms 6133 AMKL cells. (A) Parental 6133 cells were transduced with empty vector (MIG) or JAK2WT, MPLWT, JAK2V617F, 
JAK2T875N, MPLW515L, and FLT3ITDN51 retroviruses. 24 hours after infection, cells were transferred to SCF-free medium, and viable cells were 
counted daily using a trypan blue exclusion assay. (B) 6133 cells growing with SCF stimulation or transduced with MPLW515L were cytospun 
on glass slides and stained for AchE. Representative pictures are shown. Original magnification, ×100. (C) Flow cytometric analysis of phos-
pho-ERK1/2 in 6133 cells, 48 hours after transduction with the different mutants and controls. Mean fluorescence intensity is indicated on the 
histograms. (D) Growth inhibition of 6133+MplW515L cells by MAPK inhibitor. The MAPK inhibitor PD98059 was used to treat 6133+MplW515L cells. 
Growth at 48 hours compared with that of untreated cells is shown. Mean ± SD of 3 independent experiments is shown. (E) ERK1/2 phosphoryla-
tion in 6133+MplW515L cells in presence of MAPK inhibitor. 6133+MplW515L cells were treated with PD98059, and cell lysates were used in direct 
Western blot for phospho-ERK1/2, followed by total ERK1/2. (F) 6133 cells transduced with WT MPL were maintained under SCF culture and then 
stimulated with TPO (10 ng/ml). RNA was extracted before TPO stimulation (control) and 2 hours after (+TPO). Expression of Hes1 and Gata1 
transcripts was compared with Gapdh by quantitative RT-PCR. Mean ± SD of 3 independent experiments is shown. (G) 6133 cells were analyzed 
as in F and treated with MAPK inhibitor (PD98059: 5 μM) during TPO stimulation. Mean ± SD of 3 independent experiments is shown.
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Notch2, MAML1, and RBPJ as well as direct RBPJ targets, includ-
ing Hey2, Gata3, and TCFL5 (33–36) (Figure 4B). Together, these 
results show RBPJ pathway activation in human AMKL cells 
expressing the OTT-MAL fusion.
OTT-MAL cooperates with MPL signaling to induce AMKL in mice. 
Based on the low incidence of AMKL in animals expressing 
OTT-MAL alone, we hypothesized that deregulation of RBPJ 
transcription by OTT-MAL was not sufficient for development of 
AMKL and that cooperating oncogenic events were required. To 
identify such candidate events, we first used the 6133 cell line to 
screen cooperating mutations in cytokine receptors and signal-
ing molecules that have been described in human Mk malignan-
cies (18, 19, 22, 23). This included FLT3ITDN51, JAK2V617F, JAK2T875N, 
and MPLW515L. We observed that MPLW515L transduction but not 
transduction with other alleles efficiently transformed 6133 
cells, resulting in cytokine-independent growth (Figure 5A) and 
induced a megakaryocytic phenotype, as assessed in part by prom-
inent staining for AchE (Figure 5B).
To compare the pathways activated by MPLW515L and by the other 
mutants in the context of OTT-MAL, we assessed phosphoryla-
tion levels of several relevant signaling transduction intermediates, 
including ERK1/2 (MAPK pathway), STAT3 and STAT5 (STAT 
pathway), and S6 (PI3K pathway) by flow cytometry on 6133 cells 
stably transduced with FLT3ITDN51, JAK2V617F, JAK2T875N, or MPLW515L, 
respectively. ERK1/2 was markedly more activated by MPLW515L 
than by the other mutants, which did not confer factor-indepen-
dent growth to 6133 cells (Figure 5C), whereas activation of the 
STAT or PI3K pathway was more uniform among all the mutants 
(Supplemental Figure 5). To further delineate the importance 
of the pathway activation in this context, we tested the effect of 
MAPK inhibitors. We observed that the MAPK inhibitor PD98059 
inhibited the growth of 6133 cells expressing MPLW515L and ERK1/2 
phosphorylation in a dose-dependent manner (Figure 5, D and E). 
Of note, stimulation of 6133 cells expressing the WT MPL recep-
tor with TPO also induced proliferation (Figure 5A), indicating 
that proliferation was mediated by activation of the TPO/MPL sig-
naling pathway rather than specifically by the MPLW515L mutant. 
Interestingly, TPO stimulation of 6133 cells expressing WT MPL 
led to a rapid increase in Hes1 transcript but not Gata1 transcript 
(Figure 5F). This increase was inhibited by treatment with MAPK 
inhibitors (Figure 5G). Taken together, these results indicate that 
activation of the MPL/MAPK signaling pathway is important for 
megakaryoblastic transformation and increases HES1 transcrip-
tion in the context of OTT-MAL.
To corroborate cooperativity between MPL signaling and 
OTT-MAL in primary hematopoietic cells in vivo, BM cells from 
2-month-old nonleukemic OM or WT littermates were trans-
duced with retroviruses harboring the MPLW515L allele and trans-
planted into lethally irradiated WT C57BL/6 recipients (termed 
OM+MPLW515L or WT+MPLW515L, respectively). In the C57BL/6 
background BM transplant model, MPLW515L induced an MPD 
with leukocytosis, polycythemia, and marked thrombocytosis 
similar to that reported in the BALB/c background (23), albeit 
with a longer latency (median = 60 days; Supplemental Figure 6). 
In both the WT and OM contexts, the animals showed compa-
rable degrees of leukocytosis, polycythemia, thrombocythemia, 
and splenomegaly, whereas the degree of hepatomegaly was sig-
nificantly increased when OM cells were used (Figure 6, A and 
B, and Supplemental Figure 6). In contrast, when MPLW515L and 
OTT-MAL were coexpressed, flow cytometric analysis of spleno-
cytes showed a significant shift toward immature progenitors as 
assessed by a marked increase in c-Kit+ staining in OM+MPLW515L 
animals (Figure 6C and Supplemental Figure 7A), and the dis-
ease phenotype was more severe in this context, as indicated by 
a substantial increase in the number of CD41+, CD71+Ter119–, 
and Mac1+Gr1+ cells when compared with expression of MPLW515L 
alone. We next performed multiparameter flow analysis on BM 
or spleen cells, respectively, to phenotypically characterize hema-
topoietic progenitor populations. In contrast with WT+MPLW515L 
animals, which showed an increase in the common myeloid 
progenitor (CMP) population, OM+MPLW515L animals showed 
a preferential increase in the Mk-erythrocyte progenitor (MEP) 
population in both BM and spleen (Figure 6D and Supplemental 
Figure 8). In addition, MkP that were specifically engaged in the 
Mk differentiation downstream of the MEP (37) were markedly 
expanded in OM+MPLW515L animals compared with WT+MPLW515L 
animals (Figure 6E and Supplemental Figure 8).
Histopathologic analysis of BM, spleen, and liver from 
WT+MPLW515L or OM+MPLW515L animals showed infiltration with 
an admixture of megakaryocytic, erythroid, and myeloid elements 
(data not shown). Immunochemistry for vWF on spleen sections 
showed an increase in the number of mature polyploid Mks in 
WT+MPLW515L animals, whereas OM+MPLW515L animals showed, in 
addition, the presence of numerous hypolobated immature mega-
karyoblasts (Figure 6F and Supplemental Figure 9). Together, these 
data demonstrate that in the WT C57BL/6 background, MPLW515L 
induces an MPD characterized by thrombocytosis and associated 
with expansion of the CMP population. In contrast, coexpression 
of MPLW515L with OTT-MAL resulted in expansion of the MEP and 
MkP progenitor populations and evidence of transformation of 
the MPD phenotype into AMKL.
To further annotate malignant transformation, secondary 
transplantation was performed into sublethally irradiated recipi-
ents using 1 × 106 splenocytes from primary animals. Second-
ary OM+MPLW515L animals developed a disease with leukocyto-
sis and disease latency similar to that observed in the primary 
OM+MPLW515L animals (Figure 7, A and C). However, in striking 
contrast with primary recipients, secondary recipients developed 
thrombocytopenia (Figure 7B). In control experiments, secondary 
WT+MPLW515L or OM+MPLWT animals showed no sign of disease for 
over 200 days, indicating that the MPLW515L-induced MPD was not 
transplantable. Compared with control animals, flow cytometry 
analysis of secondary OM+MPLW515L splenocytes showed abnor-
mal CD41+, CD42b+, CD41/CD61+, or CD9+ populations, a frac-
tion of which were also c-Kitlo/+ (Figure 7D, Supplemental Figure 
7B, and Supplemental Figure 10). These cells also expressed the 
CD71 marker but not Ter119, Mac1, or Gr1 markers. In agreement 
with these observations, histopathologic analysis demonstrated 
that BM, spleen, and liver were heavily infiltrated with immature 
hypolobated vWF+ megakaryoblasts (Figure 7E and Supplemental 
Figure 10), with a striking reduction in median polyploidy (Figure 
7F) and fibrosis (Figure 7G and Supplemental Figure 11). Southern 
blot analysis of DNA from BM cells showed over 10 viral integra-
tion sites in primary and secondary animals and suggests that the 
disease is oligo/polyclonal (Supplemental Figure 12). Transplanta-
tion into tertiary recipients resulted in a similar phenotype as in 
the secondary recipients of OM+MPLW515L cells, albeit with a shorter 
latency (median = 38 days; Figure 7C). Collectively, these data show 
that coexpression of OTT-MAL and an activated MPL mutant 
induces AMKL with characteristic features of the human disease.
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Figure 6
Coexpression of MPLW515L with OTT-MAL results in AMKL in vivo. (A) Representative pictures of spleens from animals transplanted with OM 
or WT BM cells transduced with MPLW515L at 60 days after transplant. (B) Mean ± SD of liver weights (n = 5). (C) Flow cytometry analysis of 
splenocytes at 60 days after transplantation. Experiments were performed in triplicate, and a representative analysis is shown. Percentages of 
live cells are indicated. (D) Multiparameter flow analysis of BM CMP, granulocyte-macrophage progenitor (GMP), and MEP populations. Experi-
ment was performed in duplicate and a representative analysis gated on PI–Lin–Sca–c-Kit+ cells is shown. Percentages of PI–Lin–Sca–Kit+ cells 
are indicated. (E) Multiparameter flow analysis of the BM MkP population. MkP are defined as PI–Lin–Kit+CD9+FcγRII/IIIloCD41+. Percentages 
of Lin–Kit+CD9+ cells are indicated. (F) vWF immunohistochemistry on spleen sections. Central panels show maturing polyploid Mks. Far right 
panel shows abnormal immature hypoploid Mks. Original magnification, ×1000.
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Discussion
AMKL is generally associated with a poor prognosis, and its fre-
quency may be underrepresented because of its complex clinical 
presentation and the difficulty in interpreting diagnostic mate-
rial (38). Challenges in understanding the molecular basis of 
AMKL derive in part from the difficulty in obtaining adequate 
tissue samples derived from the fibrotic BM of patients. The 
identification of the OTT-MAL fusion in a subset of AMKL (5–7) 
provided a basis for development of a murine model of disease 
that could be used to increase understanding of the molecular 
pathogenesis of AMKL and potentially to provide insights into 
alternative therapeutic approaches.
We have observed that expression of OTT-MAL from its endog-
enous promoter results in abnormal megakaryopoiesis during 
embryonic and adult development but rarely causes AMKL. Sev-
eral observations could explain the low efficiency of transforma-
tion of the Mk lineage in the context of the OTT-MAL fusion 
alone. It is possible that mutations associated with infant mega-
Figure 7
OTT-MAL+MPLW515L–induced AMKL shows characteristics of human AMKL. (A) White blood counts in secondary recipients. Mean ± SD of 5 ani-
mals is shown. (B) Platelet counts in secondary recipients. Mean ± SD of 5 animals is shown. (C) Kaplan-Meier survival curves of secondary and 
tertiary transplant recipients. (D) Flow cytometry analysis of splenocytes at 40 days after transplantation. Percentages of live cells are indicated. 
(E) vWF immunohistochemistry on spleen sections from secondary recipients. Original magnification, ×1000. (F) Ploidy analysis was performed 
by flow cytometry using propidium iodide (PI). Histograms show a representative analysis gated on 10,000 CD41+ cells. (G) Histopathologic 
analysis of BM reticulin fibrosis in secondary recipients. Original magnification, ×100. (H) Proposed model of leukemogenesis by OTT-MAL. In 
WT cells, repressor complexes are recruited to RBPJ in the absence of Notch stimulation. Following Notch stimulation, intracellular Notch (ICN) 
translocates to the nucleus, displaces corepressors, and binds RBPJ to allow recruitment of the coactivator MAML and expression of target 
genes. We propose that OTT-MAL aberrantly activates RBPJ-mediated transcription in the absence of Notch stimulation and leads to increased 
differentiation of hematopoietic progenitors to the Mk lineage. Full AMKL transformation requires additional cooperating events (i.e., activation 
of MPL signaling). Minus sign indicates inhibition of transcription; plus signs indicate activation of transcription.
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karyoblastic leukemia preferentially target the fetal Mk compart-
ment but have minimal phenotypic effects and transforming 
efficiency in the adult hematopoietic compartment. Biological 
differences between adult and fetal Mk precursors (39) as well as 
different microenvironmental influences may thus be crucial for 
transformation of the megakaryocytic lineage. In support of this 
hypothesis, other human Mk lineage disorders, including throm-
bocytopenia associated with the thrombocytopenia and aplasia of 
the radius (TAR) syndrome or the transient MPD in DS patients, 
are observed in infancy but often resolve spontaneously during 
childhood (40, 41). In addition, similar findings were reported 
for a Gata1s knockin mouse model, in which developmentally 
restricted abnormalities in megakaryopoiesis were observed but 
not leukemic transformation (42).
The observation that OTT-MAL animals develop malignancy 
at a low frequency underscores the requirement for cooperating 
mutations to achieve transformation to AMKL. In support of 
this hypothesis, several mutations in tyrosine kinases and sig-
naling molecules have been identified in patients with AMKL 
and Mk malignancies (18, 19, 22, 23). We used a candidate gene 
approach to address the potential for cooperativity based on 
previously reported activating alleles in other megakaryocytic 
malignancies. Our data indicate that OTT-MAL cooperates 
only with a limited subset of activated signaling molecules. In 
particular, we observed that coexpression of OTT-MAL with an 
MPL mutant generates a fully penetrant and rapidly fatal disease 
closely resembling human AMKL. MPL is essential for normal 
Mk development, and activating MPL mutations are found in 
a spectrum of Mk disorders, including AMKL (21, 23, 43). Our 
results suggest that a basis for complementation of OTT-MAL 
with activated MPL might lie in the strong activation of the 
MAPK pathway. In keeping with this hypothesis, MAPK path-
way activation has been shown to favor Mk differentiation (44, 
45) and to control the activity of serum response factor and 
its cofactors (8, 9, 46), suggesting that it could synergize with 
OTT-MAL. Together, these observations suggest that AMKL 
pathogenesis by OTT-MAL may be associated with pathogenetic 
events leading to the activation of the MAPK pathway.
One of the most intriguing pathogenetic insights gleaned from 
the OTT-MAL mouse model is the involvement of the RBPJ tran-
scription factor in transformation of the megakaryocytic lineage 
through interaction with OTT-MAL and aberrant increases of RBPJ 
transcriptional activity. Activation of RBPJ-mediated transcrip-
tion by OTT-MAL is also required for the growth of AMKL cells 
derived from leukemic animals. Thus, the transcriptional program 
engaged by RBPJ is important for sustaining the proliferation of 
OTT-MAL–transformed cells. Of note, OTT was recently reported 
to modulate Notch-induced transcriptional activation and thereby 
affect myeloid differentiation (13, 47). The N-terminal portion of 
OTT, containing the RRM domains, is required for interaction of 
OTT-MAL with RBPJ, and the TAD of MAL (8) is necessary for 
activation of RBPJ transcription, suggesting that OTT-MAL aber-
rantly recruits transcriptional coactivators to regulatory elements 
of genes normally controlled by RBPJ in the absence of Notch sig-
naling (Figure 7H). Although RBPJ activation by OTT-MAL may 
not strictly mimic activation by the canonical Notch pathway and 
the essential RBPJ targets for leukemogenesis by OTT-MAL remain 
to be identified, this mechanism is reminiscent of constitutive 
activation of RBPJ transcription by several viral proteins including 
EBNA2 (Epstein-Barr virus) and RTA (Kaposi virus) (48).
RBPJ is an essential mediator of the canonical Notch pathway 
that has been implicated in normal developmental processes (33, 
49) and in cancer (26, 50). We have recently demonstrated that 
canonical Notch signaling specifies Mk fate of HSCs through 
RBPJ-dependent mechanisms (51). We now show that several 
RBPJ pathway genes are specifically upregulated in human 
AMKL patient cells associated with the t(1;22)(p13;q13) as com-
pared with DS-AMKL, the other subgroup of childhood AMKL. 
In our knockin model, we show that OTT-MAL–expressing 
hematopoietic progenitors have a differentiation bias toward 
the megakaryocytic lineage. Together, these results support 
the notion that aberrant activation of RBPJ transcription by 
OTT-MAL plays a role specifically in Mk transformation by 
skewing commitment of hematopoietic progenitors preferen-
tially to the megakaryocytic lineage.
In toto, this knockin model of OTT-MAL expression provides 
important biological insights into what we believe is a novel mech-
anism of leukemogenesis of the Mk lineage and should be a use-
ful tool for testing therapeutic approaches for the treatment of 
human AMKL that may include inhibition of RBPJ and the MAPK 
pathway, among others.
Methods
Targeting construct. A 15-kb genomic DNA fragment containing the 
murine Ott locus was obtained by screening of a phage l mouse genomic 
DNA library. A 6.9-kb EcoRI-BamHI fragment representing the 5′ homol-
ogy arm was subcloned into a pBluescript KS vector along with a 5.4-kb 
BamHI-AvrII fragment representing the 3′ homology arm. The human 
MAL cDNA (NCBI nucleotide sequence number AJ297257) was obtained 
by screening of a phage l leukocytes cDNA library (Stratagene; gift from 
S. Gisselbrecht and G. Courtois, INSERM, Paris, France). An XhoI-BamHI 
fragment containing exons 4 to 15 of MAL was introduced into the 
pBS302 vector (Life Technologies) in 3′ of the transcriptional termina-
tion STOP cassette. A SalI-SalI fragment containing a loxP site was then 
introduced in between the STOP cassette and the MAL cDNA. A 2.1-kb 
EcoRI-HindIII fragment containing part of the Ott first intron with a BglII 
restriction enzyme site and Ott second exon was then introduced in the 
pBS302 vector upstream of the STOP cassette. A BamHI-BamHI fragment 
containing a floxed Hygromycin resistance cassette was then introduced 
into the BglII site, creating a loxP–Hygromycin–loxP–Ott Exon2–loxP–
MAL cDNA. A BamHI fragment containing this loxP–Hygromycin–loxP–
Ott Exon2–loxP–MAL cDNA was finally introduced into the BamHI site 
of the vector containing the 5′ and 3′ homology arms. All intermediates 
and final constructs were entirely resequenced.
ES cell culture and screening. A purified 21-kb SalI-NotI targeting fragment 
was electroporated into R1 ES cells by the Dartmouth College Transgenic 
Core (Dartmouth, New Hampshire, USA). For Southern blot analyses, 
genomic DNA from individual clones was digested with the restriction 
enzyme XmnI. Ott3lox/WT ES cell clones were infected with an adenovirus 
encoding the Cre recombinase (MOI of 100). Fresh medium was added 
2 hours later. 24 hours after infection, cells were trypsinized and plated 
at 1,000 cells/100-mm Petri dish. Individual colonies were replated after 
5 days and expanded, and DNA was extracted for screening by Southern 
blot as described above. C57BL/6 blastocyst injection of ES cells present-
ing a normal karyotype was performed by the Brigham and Women’s Hos-
pital Transgenic Core. Chimeras were bred with C57BL/6 mice (Charles 
River) for germline transmission. Ott3lox/WT animals were bred with EIIa-Cre 
transgenic mice (The Jackson Laboratory) to achieve transmission of the 
OTTOTT–MAL allele through germline excision. Subsequently, OM mice were 
backcrossed at least 5 generations with WT C57BL/6 animals.
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Constructs. OTT, MAL, OTT-MAL, OTT-MALΔRRM, and OTT-
MALΔTAD were cloned into the pCMX-HA or pcDNA3-HA vector. All 
constructs were confirmed by resequencing. pJH23A (4xwtRBPJLuc) was 
a gift from S.D. Hayward (Johns Hopkins School of Medicine, Baltimore, 
Maryland, USA), and MPI79-HA-dnRBPJ (dnRBPJ) was a gift from O. Alba-
gli (INSERM, Paris, France) and E. Lauret (INSERM, Paris, France) (29). 
The MSCV dnMAML1-GFP fusion was a gift from J.D. Griffin (Harvard 
Medical School, Boston, Massachusetts, USA) (31).
Notch reporter assay and TNR mice. Transfections were carried out using 
FuGENE (Roche) according to the manufacturer’s protocols. For lucif-
erase assays, HEK293 cells were plated in 6-well plates and transfected 
with 200 ng pJH23A, 40 ng pRL-TK, and 50 or 200 ng of the indicated 
plasmids in a total of 500 ng DNA. Luciferase activity was measured 
48 hours later by Dual-Luciferase Reporter Assay Kit (Promega), and 
histograms show normalized results to pRL-TK luciferase. TNR mice 
(27, 28) expressing the eGFP under the control of 4 tandem copies of 
the RBPJ binding sites were obtained from The Jackson Laboratory (no. 
005854) and crossed to OM mice.
Microarray data analysis. For microarray analysis, we used a published 
data set of AMKLs (32) (Gene Expression Omnibus accession num-
ber GSE4119). We collected raw global gene expression values (from 
Affymetrix GeneChip U133A) for t(1;22)(p13;q13) AMKL (OM-AMKL) 
samples and DS-AMKL samples. We processed these samples with the 
robust multiarray analysis (RMA) algorithm (52) using BioConductor 
software, version 2.3 (53). Using the processed data, we then performed 
GSEA (http://www.broad.mit.edu/gsea/) (54) to look for enrichment of 
a list of Notch pathway genes (Supplemental Table 1). The GSEA algo-
rithm identified a leading edge set of the genes that best distinguished 
OM-AMKL from DS-AMKL.
Immunoprecipitation and Western blot analysis. Cells were lysed in 20 mM 
Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 10% glyc-
erol (Complete; Roche), 1 mM PMSF, 1 mM sodium orthovanadate, and 
0.1 mM phenylarsine oxide. Lysates were normalized for protein content 
(BCA protein assay; Pierce, Thermo Scientific). For direct Western blot, 
500 μg (Figure 1) of total proteins was used following standard proto-
col. Anti-MAL antibodies (home-made no. 2346 directed against human 
MAL Ct portion or sc-21558; Santa Cruz Biotechnology Inc.) were used. 
For immunoprecipitation experiments, full-length or mutant HA-tagged 
OTT-MAL constructs were transfected into HEK293 cells. Protein lysates 
(1,000 μg) collected 48 hours later were immunoprecipitated with either 
RBPJ (sc-28713; Santa Cruz Biotechnology Inc.) or STAT5 (sc-835; Santa 
Cruz Biotechnology Inc.). Eluate was analyzed by Western blot for HA 
(2362; Cell Signaling Technology) and RBPJ. 50 μg of protein lysate was 
analyzed by direct Western blot to check for input. PD98059 (Calbio-
chem) was resuspended in DMSO, and an identical concentration of 
DMSO was used as control.
Chromatin immunoprecipitation analysis. 2 × 106 6133 or Ba/F3 cells were 
used for each chromatin immunoprecipitation, with 2 μg of each antibody 
and following standard procedures.
Hes1 promoter primers used for quantitative PCR were as follows: Hes1-F: 
GCAAAGCCCAGAGGAAAGAGTTAG; and Hes1-R: AGGAGAGAGG-
TAGACAGGGGATTC.
Flow cytometric analysis. Antibodies were purchased from BD except for 
FcγRII/III-PECy7 (Abcam) and goat anti-rabbit Alexa Fluor 647 (Molecular 
Probes; Invitrogen). Staining for flow cytometry was performed in 1× PBS 
with 2% FBS, except when otherwise mentioned. HSCs were stained for 
multiparameter flow analysis as previously described (20, 55), then ana-
lyzed on a highly modified double-laser (488-nm/350-nm, Enterprise II; 
and 647-nm, Spectrum; DakoCytomation) FACS (Moflo-MLS; DakoCyto-
mation or FACSAria; BD Biosciences). Cell populations were defined as fol-
lows: HSC, Lin–IL7R–Sca-1+c-Kit+; CMP, Lin–Sca-1–c-Kit+CD34+FcγRII/IIIlo; 
granulocyte-macrophage progenitor (GMP), Lin–Sca-1–c-Kit+CD34+FcγRII/
IIIhi; MEP, Lin–Sca-1–c-Kit+CD34–FcγRII/IIIlo. 100 HSC (Lin–Sca-1+c-Kit+) 
were double sorted directly onto plates containing MethoCult M3434 
(STEMCELL Technologies) supplemented with 10 ng/ml rhIL-11, 10 ng/ml 
rmGM-CSF, and 10 ng/ml rmTPO (STEMCELL Technologies). Colonies 
on triplicate plates were scored 7 days later.
MkP analysis was performed as previously described (37) with dif-
ferent fluorochrome-coupled antibodies to accommodate the pres-
ence of GFP in the cells: PECy5.5-conjugated lineage antibodies (Gr1, 
Ter119, CD19, B220, CD4, CD8, and CD3); biotin-CD9/APCCy7-avidin; 
CD41-PE; c-Kit-APC; and FcγRII/III-PECy7. MkPs were defined as Lin– 
c-Kit+CD9+FcγRII/IIIloCD41+.
For ploidy analysis, cells were first stained with CD41 antibody, then 
stained with APC-conjugated secondary antibody. Cells were then incu-
bated 30 minutes in a 0.1% sodium citrate solution containing 50 μg/ml 
of RNAse and 50 μg/ml of propidium iodide. Analysis of ploidy was per-
formed using 1 × 104 CD41+ cells. For phospho-flow analysis, 6133 cells 
were transduced with the different mutant viruses and analysis was per-
formed 48 hours later. Cells were starved for 2 hours in RPMI 1640 plus 1% 
BSA for 2 hours, fixed with 1% methanol-free formaldehyde (Polysciences 
Inc.), permeabilized with 100% methanol, and stained with phospho-
specific antibodies (Cell Signaling Technologies): p-ERK1/2 (no. 9101), 
p-STAT3 (no. 9131), p-STAT5 (no. 9351), and p-S6 (no. 2211) followed by 
secondary goat anti-rabbit Alexa Fluor 647 antibody (Molecular Probes; 
Invitrogen). Analysis was gated on GFP+ cells. Acquisition of the data was 
performed on a FACSCalibur (BD Biosciences); data were analyzed with 
FlowJo software, version 8.5.3.
Colony assays. Single-cell suspensions were prepared from E12.5 fetal liv-
ers by passing cells sequentially through 18-gauge, 21-gauge, and 27-gauge 
needles. Cells were incubated with Red Blood Cells Lysis Buffer (Puregene; 
QIAGEN) for 5′ on ice and then resuspended in culture medium.
For myeloid colony assays, 2 × 104 cells were plated in MethoCult 3434 
(STEMCELL Technologies) supplemented with TPO, and IL-11 and colo-
nies were scored after 7 days. For Mk colony assays, 2.2 × 105 cells were mixed 
with MegaCult-C (STEMCELL Technologies) containing TPO, IL-11, IL-3, 
and IL-6, according to manufacturer’s recommendation, and plated onto 2 
double-chamber culture slides; colonies were enumerated after 8 days.
Staining and immunohistochemistry. AchE staining of MegaCult cultures 
or cytospun cells was performed following manufacturer’s recommen-
dations (STEMCELL Technologies). Blood smears were stained with 
Wright-Giemsa Stain (Sigma-Aldrich). H&E staining, reticulin staining, 
and vWF (Dako) immunohistochemistry on paraffin-embedded tissue 
sections were performed by the Brigham and Women’s Histopathology 
Core Facility following standard procedures. Images of histologic slides 
were obtained on a Nikon Eclipse E400 microscope equipped with SPOT 
RT color digital camera (model 2.1.1; Diagnostic Instruments Inc.). The 
microscope was equipped with a 10x/22 NA ocular lens. ×100 images were 
obtained with a 10x/0.25 objective lens, ×1000 images were obtained with 
a 100x/1.4 objective lens with oil (Trak-300; Richard-Allan Scientific). 
Images were analyzed using Adobe Photoshop 6.0.
Transplantation and viral infection. 1 × 106 splenocytes from 6133 (OTTOTT–MAL) 
and 6127 (WT littermate) animals were injected into sublethally irradiated 
SCID recipients (C.B. 17 Fox Chase SCID, CD17SC.M; Taconic).
For cooperation studies, viral supernatants were obtained as described 
(19, 20). 6133 cells were mixed with viral supernatants, spinfected for 
90 minutes at 1800 g, and returned to the incubator for 3 to 5 hours. 
48 hours after infection, cells were transferred to SCF-free medium, and 
viable cells were counted every day using trypan blue staining. For BM 
transplant, 8- to 10-week-old OTTOTT–MAL or WT littermate donor mice 
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were injected with 5-FU 5 days prior to BM collection. On day 0, primary 
BM cells were obtained from femurs and tibiae and cultured overnight 
in RPMI 1640 supplemented with 10% FBS+IL-3, IL-6, and SCF after 
lysis of red blood cells. Cells were mixed with identical titer viral super-
natants 3 times on day 1 and day 2 and spinfected for 90 minutes at 
1800 g each time. After the second spinfection, 1 × 106 cells were injected 
in the tail veins of lethally irradiated C57BL/6 recipients. Nonlethal eye 
bleeds were performed using EDTA or heparin-coated capillary tubes, 
and blood counts were performed within 30 minutes on a HemaVet 
HV950FS (Drew Scientific Group). Approval for the use of animals in 
this study was granted by the Children’s Hospital Boston Animal Care 
and Use Committee (Boston, Massachusetts, USA).
Statistics. 2-tailed Student’s t tests were performed using the program 
GraphPad Prism, version 4.0c (GraphPad Software); P < 0.05 was consid-
ered significant.
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